section name header

Pronunciation

droe-PER-i-dole

Classifications

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: butyrophenones

Indications

REMS


Action

  • Similar to haloperidol; alters the action of dopamine in the CNS.
Therapeutic effects:
  • Suppression of nausea and vomiting in selected situations.

Pharmacokinetics

Absorption: Well absorbed following IM administration. IV administration results in complete bioavailability.

Distribution: Appears to cross the blood-brain barrier and placenta.

Metabolism/Excretion: Mainly metabolized by the liver. Only 10% excreted unchanged by the kidneys.

Half-Life: 2.2 hr.

Time/Action Profile

(sedation)

ROUTEONSETPEAKDURATION*
IM, IV3–10 min30 min2–4 hr



*Listed as duration of tranquilization; alterations in consciousness may last up to 12 hr.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, tachycardia, QT prolongation, ARRHYTHMIAS (INCLUDING TORSADES DE POINTES)

EENT: blurred vision, dry eyes

GI: constipation, dry mouth

Neuro: extrapyramidal reactions, abnormal EEG, anxiety, confusion, dizziness, excessive sedation, hallucinations, hyperactivity, mental depression, nightmares, restlessness, SEIZURES, tardive dyskinesia

Resp: bronchospasm, laryngospasm

Misc: chills, facial sweating, shivering

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Inapsine